Form 4: Clene Director Sells Shares Under 10b5-1 Plan

Clene Inc. Director and 10% owner Chidozie Ugwumba reported sales of common stock totaling 17,110 shares across two transactions in late 2025 and early 2026, executed under a Rule 10b5-1 plan.

Summary

• Chidozie Ugwumba, a Director and 10% owner of Clene Inc. (CLNN), reported two sales of common stock.
• On December 31, 2025, 13,095 shares of common stock were sold at a price of $5.81 per share.
• On January 2, 2026, an additional 4,015 shares of common stock were sold at a price of $5.73 per share.
• Both transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following these reported transactions, 766,480 shares of common stock are beneficially owned indirectly by Symbiosis II, LLC.

Sentiment

Score: 5

Explanation: This Form 4 reports routine insider stock sales by a director and 10% owner, explicitly stating the transactions were made pursuant to a Rule 10b5-1 plan. Such plans are pre-arranged to avoid accusations of trading on material non-public information, making the sales less indicative of a negative outlook for the company. Therefore, the sentiment is neutral as it represents a scheduled event rather than an opportunistic sale.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the insider's direct stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine disclosure of insider trading activity and does not provide information directly related to broader industry trends or competitors.

Related Party Transactions

• The shares beneficially owned following the transactions are held indirectly by Symbiosis II, LLC, indicating a relationship between the reporting person and this entity.

Stakeholder Impact

• Shareholders may note the reduction in the beneficial ownership of a director and 10% owner, although the execution under a 10b5-1 plan suggests these were pre-scheduled transactions.

Key Dates

Recommendation

The filing details insider sales by a director and 10% owner, explicitly stating these transactions were executed under a Rule 10b5-1 trading plan. This significantly mitigates the typical negative interpretation of insider selling, as the sales are pre-scheduled and not based on recent material non-public information. Without additional information on the company's operational performance, financial health, or broader market conditions, this Form 4 alone does not provide sufficient grounds for a 'buy' or 'sell' recommendation. A 'hold' stance is appropriate, acknowledging the routine nature of these disclosed transactions.

Keywords

Clene Inc., CLNN, Insider Trading, Form 4, Stock Sale, Director, Beneficial Ownership, Ugwumba Chidozie, Symbiosis II, LLC, Rule 10b5-1